| Biotechnology Industry | Healthcare Sector | Mr. Yoram Drucker CEO | OTC PINK Exchange | - ISIN |
| CA Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
NurExone Biologic Inc. is a distinguished pharmaceutical technology company, launched in 2020, and situated in Toronto, Canada. The firm is at the forefront of innovation with its focus on developing groundbreaking treatments for some of the most challenging medical conditions. By leveraging cutting-edge membrane-bound extracellular vesicles technology, NurExone Biologic Inc. is committed to transforming the landscape of treatments for spinal cord injuries, brain trauma, and various neurological disorders. This technology paves the way for off-the-shelf, non-invasive solutions, offering new hope for illnesses that have long been considered untreatable or difficult to manage.
At NurExone Biologic Inc., our product development pipeline is specifically designed to address several critical areas within the realm of neurological health and recovery. Our innovative approach to treatment is built around the potent potential of membrane-bound extracellular vesicles technology. Here's a closer look at our primary focus areas: